Eli Lilly and Company invoked the US Supreme Court's recent opinion overturning the Chevron doctrine of deference in a new lawsuit challenging the US Food and Drug Administration’s determination that its investigational anti-obesity agent retatrutide is a drug, not a biologic.
In a complaint filed 3 September, Lilly asks the US District Court for the Southern District of Indiana to find that the agency improperly interpreted the Public Health Service...
Key Takeaways
-
Lilly is challenging the FDA’s determination that its investigational anti-obesity product retatrutide is a drug, not a biologic.
-
The lawsuit cites the Supreme Court’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?